Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Down Following Analyst Downgrade

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) gapped down before the market opened on Tuesday after HC Wainwright lowered their price target on the stock from $54.00 to $52.00. The stock had previously closed at $40.06, but opened at $35.80. HC Wainwright currently has a buy rating on the stock. Agios Pharmaceuticals shares last traded at $39.1180, with a volume of 575,336 shares changing hands.

AGIO has been the subject of a number of other reports. The Goldman Sachs Group increased their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Wednesday, April 1st. Royal Bank Of Canada lifted their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Truist Financial upped their price target on shares of Agios Pharmaceuticals from $36.00 to $41.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, Bank of America raised their price target on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $42.78.

Agios Pharmaceuticals News Summary

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Negative Sentiment: Agios scrapped the tebapivat sickle cell disease program after Phase 2 data failed to show a compelling benefit versus existing options, a setback that weakens a key pipeline opportunity. Article Title
• Negative Sentiment: Multiple reports highlighted the stock’s decline following the decision, with coverage emphasizing that the company is abandoning the sickle cell candidate after lackluster trial results. Article Title
• Negative Sentiment: Investor sentiment is also being dampened by the loss of a potential growth driver in sickle cell disease, even though Agios’ other PK activator, mitapivat, remains under FDA Priority Review with a PDUFA date of November 1, 2026. Article Title

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Bellevue Group AG boosted its position in Agios Pharmaceuticals by 3.5% in the third quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after buying an additional 124,586 shares during the last quarter. State Street Corp raised its position in Agios Pharmaceuticals by 37.4% during the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after buying an additional 845,433 shares during the last quarter. Erste Asset Management GmbH raised its position in Agios Pharmaceuticals by 1.4% during the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after buying an additional 40,000 shares during the last quarter. Wellington Management Group LLP lifted its stake in Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after acquiring an additional 2,049,287 shares during the period. Finally, Commodore Capital LP lifted its stake in Agios Pharmaceuticals by 6.4% during the 2nd quarter. Commodore Capital LP now owns 2,325,000 shares of the biopharmaceutical company’s stock valued at $77,330,000 after acquiring an additional 140,000 shares during the period.

Agios Pharmaceuticals Trading Down 3.5%

The firm’s fifty day moving average price is $33.58 and its 200 day moving average price is $30.56. The firm has a market capitalization of $2.14 billion, a PE ratio of -4.97 and a beta of 0.54.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.81) by $0.12. The firm had revenue of $20.75 million for the quarter, compared to analyst estimates of $13.30 million. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The business’s revenue was up 137.7% compared to the same quarter last year. On average, analysts predict that Agios Pharmaceuticals, Inc. will post -6.32 earnings per share for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.